Navigation Links
Cancer screening rates comparable for those with and without rheumatoid arthritis
Date:7/9/2012

New research reveals that rheumatoid arthritis (RA) patients do not receive fewer cancer screening tests than the general population. Results of the study, funded in part by grants from the National Institutes of Health (NIH) and published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), found that RA and non-RA patients receive routine screening for breast, cervical, and colon cancer at similar rates.

The ACR estimates that 1.3 million adult Americans are affected by RAa chronic autoimmune disease characterized by systemic inflammation of the joints that over time may damage joints, impair daily function, and cause significant disability. Medical evidence confirms that despite early and aggressive treatment, RA patients have a decreased life expectancy compared to the general population. Previous research reports that cancer is one of the main causes of death for RA patients and patients with chronic disease may not receive preventive medical services including regular screenings for cancer.

"Early detection of common cancers can improve morbidity and mortality rates in those with chronic illnesses, such as RA," said Dr. Seoyoung C. Kim with the Division of Rheumatology and Division of Pharmacoepidemiology at Brigham and Women's Hospital in Boston, Mass. "Cancer screening tests are important in detecting malignancies at early stages for both chronically ill and healthy populations."

To further understand barriers to preventative medical care and raise awareness of the importance of early cancer screenings, Dr. Kim and colleagues examined screening rates for breast, cervical and colon cancer in RA patient compared to those without the disease. Using claims data from a major insurance provider, the team identified 13,314 patients with RA patients and 212,324 non-RA patients.

Analysis shows that on average both RA and non-RA groups were screened once every three years for cervical cancer and every two years for breast cancer. Among all participants 50 years and older, 12% of RA patients and 10% of non-RA patients had at least one colonoscopy each year. Women with RA were more likely to have an annual Pap smear, mammogram, fecal occult blood (FOB) test and colonoscopy than those without RA. Male RA patients were also more likely to have a colonoscopy compared to than those without RA.

"Our findings indicate that RA patients were regularly screened for cervical, breast and colon cancer as recommended by the American Cancer Society," concludes Dr. Kim. "Cancer screenings rates among patients with RA were similar to the general population, which is different than previously published results. However, these earlier studies did not compare rates of cancer screenings in RA patients with a non-RA group." The authors suggest that patients and physicians be aware of the importance of preventive healthcare in patients with chronic diseases such as RA. They caution that results of this should not be generalized to those without medical insurance.


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Regulation by proteins outside cancer cells points to potential new drug target
2. Decreasing cancer risk associated with inflammatory bowel disease
3. Better treatment for brain cancer revealed by new molecular insights
4. Researchers find new target deep within cancer cells
5. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
6. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
7. Fertility drug usage and cancer risk
8. Scientists develop mouse model that could lead to new therapies for liver cancer
9. Can Fertility Treatments Influence Later Breast Cancer Risk?
10. Worlds fastest camera, created by UCLA engineers, used to detect rogue cancer cells
11. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: